Overview: The Management of the HIV-Positive Patient with Neuropsychiatric Impairment

Ostrow, David G.; AtkinsonIII, J. Hampton; Grant, Igor

doi:10.1007/978-1-4757-9386-4_10

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1994

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This lower dose is similar to the lower doses used to treat older schizophrenic patients (Jeste et al 1993) and patients with dementia (Wragg and Jeste 1988). Our fmdings are consistent with the recommendations of Ostrow et al (1988) and Gilmer and Busch (1991) that psychotic symptoms in HIV -positive patients be treated with low dosages of neuroleptics. Why HIV-positive patients re quire, or more likely, tolerate lower doses of antipsy chotic is unclear, but this could be related to phar macokinetic changes due to chronic diseases (e.g., decreased hepatic clearance).…”

Section: Discussionsupporting

confidence: 89%

Neuroleptic Treatment of HIV-Associated Psychosis

Sewell

Jeste

McAdams

et al. 1994

Neuropsychopharmacol

Self Cite

View full text Add to dashboard Cite

The aim of this rater-blinded randomized study was to evaluate the efficacy and side effects of haloperidol and thioridazine in the treatment of new-onset psychosis in HIV-positive individuals. Participants were 13 men who had no history of psychosis prior to infection with HIV, and whose psychosis was not attributable to delirium or to non-HIV-related organic factors. Participants were evaluated at baseline after at least one month without neuroleptic treatment and then weekly for six weeks of the experimental treatment using several rating scales. The mean daily dose in chlorpromazine equivalents was

show abstract

Section: Discussionsupporting

confidence: 89%